What NeoSome Life Sciences does

NeoSome Life Sciences is a preclinical contract research organization (CRO) founded in 2014 and headquartered in Billerica, Massachusetts, with a satellite mailing address in Lexington. The company provides both in-vivo and in-vitro drug discovery support services to pharmaceutical and biotechnology companies, and to a lesser extent academic institutions, operating from a 30,000 sq. ft. AAALAC-, OLAW-, and USDA-compliant facility that includes a BSL-2 suite, clean rooms, surgical facilities, and a dedicated vivarium. Its service portfolio spans five core areas — infectious disease, oncology, pharmacology, in vitro services, and additional disease models (metabolic, inflammation, behavioral) — with technical capabilities including IVIS imaging, Meso Scale Discovery (MSD) multiplexing up to 10 analytes, 14-color flow cytometry, ELISA, Western blot, cell-based assays, clinical chemistry, and hematology.

The business model is a professional services / project-based contract research model. NeoSome does not publish pricing; engagements are scoped through direct consultation with study directors and scientific account managers, with revenue tied to study design complexity, animal models used, and assay requirements. Customer segments are horizontally distributed across large pharma, emerging biotech, and academia, with go-to-market executed through a consultative direct sales motion supplemented by LinkedIn presence, blog content marketing, email newsletters, and conference participation (e.g., RESI).

Operationally, NeoSome has invested in scale (new 2022 facility), breadth (expanded in-house in-vitro menu in 2023), and compliance (AAALAC accreditation in October 2024). The company is privately held with no disclosed funding rounds, no named customers, no revenue disclosure, and no disclosed ownership or investor base, limiting external visibility into financial trajectory.

Name

NeoSome Life Sciences

Legal name

NeoSome Life Sciences

Website

https://neosomels.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

NeoSome Life Sciences is a preclinical contract research organization providing in-vivo and in-vitro drug discovery services — including infectious disease, oncology, pharmacology, and bioanalytical assays — to pharmaceutical and biotechnology companies from its AAALAC-accredited facility in Billerica, Massachusetts.

Ownership category

akta.pro rank

Product category

Preclinical Contract Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

In Vivo Pharmacology (Efficacy/PD Models) (HLAGAFAA)

akta.pro secondary industries

DMPK / ADME & Bioanalysis (HLAGAFAC), In Vitro Toxicology (Cell-based/Organ-on-chip) (HLAGAFAJ), In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK)

Keywords

• Preclinical contract research
• Drug discovery services
• Animal disease models
• In vivo efficacy studies
• In vitro bioanalytical assays

Headquarters

HQ city

Lexington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Contract Research Services: Project-based contract research services where NeoSome conducts preclinical studies on behalf of pharmaceutical and biotech clients. Services span multiple stages of drug discovery including proof of concept, in-vitro assays, and drug efficacy evaluations in animal models of human disease. Revenue is generated through individual study contracts with pricing based on study design complexity, animal models used, and assay requirements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

NeoSome Life Sciences is a contract research organization that conducts preclinical in-vivo and in-vitro studies on behalf of pharmaceutical and biotechnology clients. Services span the drug discovery pipeline and include infectious disease models, oncology models, pharmacology and PK studies, in-vitro bioanalytical assays (MSD, flow cytometry, ELISA, Western blot, cell-based assays, clinical chemistry, hematology), and specialized animal disease models in metabolic, inflammation, and behavioral research. Each engagement is custom-designed with the company's study directors and scientific staff guiding animal model selection, protocol design, execution, data analysis, and interpretation.

Product overview

NeoSome Life Sciences is a full-service contract research organization (CRO) providing preclinical drug discovery support through multiple service platforms. The company operates a unified service offering organized around five core research areas: Infectious Disease Research Services, Oncology Research Services, Pharmacology Services, In Vitro Services Platform, and Additional Research Models. The In Vitro Services Platform encompasses sub-services including MSD (Meso Scale Discovery), Flow Cytometry, Western Blot, ELISA, Clinical Chemistry & Hematology, and Cell-Based Assays. These services are designed to work together across drug discovery stages from proof of concept through in vivo efficacy evaluation, with the company supporting both standard assay panels and custom assay development.

Differentiator

Problem solved

Functional benefit

Products and services

• Infectious Disease Research Services Anti-infective agent evaluation combining in-vitro assays (MICs, MBCs, PAEs, Time Kill curves, Checkerboard assays, susceptibility testing) with in-vivo models (Mouse Protection Test, rodent pulmonary models, kidney infection models, C. difficile models, neutropenic models, fungal infection models) for pharmaceutical and biotech clients developing anti-infective drugs.
• Oncology Research Services Broad portfolio of oncology models covering all research phases, from cell toxicity assays to efficacy models and pharmacodynamic assessments, using IVIS imaging technology for orthotopic tumor imaging, surgical implantation visualization, and longitudinal tumor burden tracking. Designed for pharma and biotech oncology programs.
• Pharmacology Services Pharmacology testing including tolerability assessments, formulation evaluations, and single- and multi-dose pharmacokinetic studies administered via IV, PO, SC, IP, IM, and ID routes across rodent species, supporting preclinical drug development programs.
• In Vitro Services Platform Unified in-house in-vitro services platform providing high sensitivity and specificity using standard and custom panels with low sample volumes, supporting drug discovery programs through bioanalytical assays (MSD, flow cytometry, ELISA, Western blot, cell-based assays, clinical chemistry, hematology).
• Meso Scale Discovery (MSD) Service Electrochemiluminescence-based protein detection offering higher sensitivity than traditional ELISA, with multiplexing capability up to 10 analytes from a single small sample, run on the MESO QuickPlex SQ 120MM platform for pharma and biotech biomarker work.
• Flow Cytometry Service Multi-parameter flow cytometry supporting up to 14 colors for immunophenotyping and cell profiling, with applications in immunotherapy including CAR-T, CAR-NK, bi-specific T Cell engagers, checkpoint inhibitors, vaccines, and immune modulators.
• Western Blot Service SDS-PAGE and Western blot analysis for protein target isolation, detection, and quantitation in test samples for pharma and biotech drug discovery programs.
• ELISA Service Kit-based or custom ELISA assays for detection and quantitation of protein biomarkers, using a spectrophotometer imaging system capable of both visible and chemiluminescent signals.
• Clinical Chemistry & Hematology Service In-house clinical chemistry analyzer with full test panels (liver, kidney, endocrine, metabolic, toxicology) paired with a HemaVet hematology analyzer for complete blood counts across multiple species, using fresh sample protocols that require smaller sample volumes for reproducible results.
• Cell-Based Assays Service Drug-cell interaction assays including cytotoxicity assays, MTT assays, IC50 determinations, and clonogenic assays with customizable parameters to support pharma and biotech discovery research.
• Additional Research Models Specialized animal disease models including Metabolic Disease Models (DIO, STZ-induced diabetes, Zucker Fatty Rat, db/db, ob/ob), Inflammation Models (LPS, AIA, EAE, DTH, CIA, CAIA), and Behavioral Models (Forced Swim Test, Elevated Plus Maze, Modified Irwin Battery, PanLab Smart Track), with real-time animal tracking and customizable analysis.

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Market position

Strengths4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/neosome-life-sciences

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeoSome Life Sciences